<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2019-08-06">6 August 2019</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tingyan</forename><surname>Shi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Gynecology Oncology</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution" key="instit1">Ovarian Cancer Program</orgName>
								<orgName type="institution" key="instit2">Zhongshan Hospital</orgName>
								<orgName type="institution" key="instit3">Fudan University</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rong</forename><surname>Jiang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Gynecology Oncology</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution" key="instit1">Ovarian Cancer Program</orgName>
								<orgName type="institution" key="instit2">Zhongshan Hospital</orgName>
								<orgName type="institution" key="instit3">Fudan University</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong</forename><surname>Pu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Wuxi Caner Hospital</orgName>
								<address>
									<settlement>Jiangsu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huijuan</forename><surname>Yang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dongsheng</forename><surname>Tu</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Mathematics and Statistics</orgName>
								<orgName type="institution">Queen&apos;s University</orgName>
								<address>
									<settlement>Kingston</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhiyuan</forename><surname>Dai</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Suzhou Municipal Hospital</orgName>
								<address>
									<settlement>Jiangsu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yunlang</forename><surname>Cai</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Zhongda Hospital Southeast University</orgName>
								<address>
									<settlement>Jiangsu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuqin</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Gynecology Oncology</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution" key="instit1">Ovarian Cancer Program</orgName>
								<orgName type="institution" key="instit2">Zhongshan Hospital</orgName>
								<orgName type="institution" key="instit3">Fudan University</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xi</forename><surname>Cheng</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huixun</forename><surname>Jia</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Clinical Statistics Center</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Clinical Statistics Center</orgName>
								<orgName type="institution">Shanghai General Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruiqin</forename><surname>Tu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Gynecology Oncology</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution" key="instit1">Ovarian Cancer Program</orgName>
								<orgName type="institution" key="instit2">Zhongshan Hospital</orgName>
								<orgName type="institution" key="instit3">Fudan University</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huaying</forename><surname>Wang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><surname>Tang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuting</forename><surname>Luan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Gynecology Oncology</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution" key="instit1">Ovarian Cancer Program</orgName>
								<orgName type="institution" key="instit2">Zhongshan Hospital</orgName>
								<orgName type="institution" key="instit3">Fudan University</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shumo</forename><surname>Cai</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rongyu</forename><surname>Zang</surname></persName>
							<email>ryzang@yahoo.com</email>
							<idno type="ORCID">0000-0002-1334-2398</idno>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Gynecology Oncology</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution" key="instit1">Ovarian Cancer Program</orgName>
								<orgName type="institution" key="instit2">Zhongshan Hospital</orgName>
								<orgName type="institution" key="instit3">Fudan University</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2019-08-06">6 August 2019</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1038/s41416-019-0543-1</idno>
					<note type="submission">Received: 3 April 2019 Revised: 9 July 2019 Accepted: 18 July 2019</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the frontline therapy. In this phase 2 trial, 218 patients with FIGO IIIC-IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49-1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BACKGROUND</head><p>To date, three randomised phase 3 clinical trials have demonstrated that intraperitoneal (IP) chemotherapy is an effective management for epithelial ovarian cancer after primary optimal debulking surgery. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref> However, the fourth phase 3 trial, GOG252 that reduced the cisplatin dose from 100 mg/m 2 to 75 mg/m 2 neither showed a survival benefit in IP Carboplatin nor in IP Cisplatin, <ref type="bibr" target="#b3">4</ref> which highlights the controversy of IP chemotherapy in ovarian cancer. Our recent study reported disease progression delayed by additional dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) with weekly cisplatin and etoposide (AICE trial) in the front-line setting. <ref type="bibr" target="#b4">5</ref> The primary endpoint of the AICE phase 2 trial showed a 28% increase in 12-month nonprogression rate in ovarian cancer patients in favour of the DD-EPIC group [hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.27-0.82, P = 0.005]. Despite the increased toxicity in the DD-EPIC group, most toxicities were acceptable, and the completion rate was much higher than that in GOG172, with the infection rate 11.6% in AICE vs. 16% in GOG172, and a completion rate of IP chemotherapy 90.6% vs. 42%, respectively. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b4">5</ref> The mean inpatient cost in the DD-EPIC group was not much higher than that in the control group ($9338.2 vs. $7424.4).</p><p>The AICE trial was also designed to detect the improvement of progression-free and overall survival (OS). Here, we present the final OS and updated PFS data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial design and procedure</head><p>The AICE study was an investigator-initiated multicentre, randomised, unblinded, controlled, phase 2 trial to assess the efficacy and safety of DD-EPIC in the front-line therapy of advanced ovarian cancer. The study design and the detailed inclusion and exclusion criteria, as well as the baseline characteristics and primary outcome results have been previously described. <ref type="bibr" target="#b4">5</ref> Briefly, eligible patients were aged 18-75 years; with stage IIIC and IV primary epithelial ovarian, fallopian tube or peritoneal cancer, excluding lymph node metastasis alone; an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; no more than three cycles of chemotherapy prior to surgery; with optimal (≤1 cm residual disease) debulking surgery. Randomisation was done using 1:1 allocation, and was performed after debulking surgery. DD-EPIC was defined to be started at 5-10 days after surgery, and no more than 14 days postoperative for those with bowel resection.</p><p>After randomisation, patients received either four doses of weekly DD-EPIC with cisplatin 50 mg/m 2 and etoposide 100 mg/ m 2 followed by six cycles of IV carboplatin AUC 5 and paclitaxel 175 mg/m 2 or docetaxel 60-75 mg/m 2 every 3 weeks (the DD-EPIC group) or standard six cycles of IV carboplatin AUC 5 and paclitaxel 175 mg/m 2 or docetaxel 60-75 mg/m 2 every 3 weeks (the IV group).</p><p>Each patient was followed every 3 months over the first 5 years, and then every 6 months thereafter, during which physical examination, CA125 levels and radiological images (ultrasound, computed tomography or magnetic resonance imaging) were performed. Progression was defined by one or more of the following items: physical examination, elevated CA125 levels according to the Gynecologic Oncology Intergroup criteria and/or radiological images. Each progression event was confirmed by centre principle investigators.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>The trial was structured a priori to assess PFS and OS, as the secondary outcomes. PFS was defined as the time from randomisation to first recurrence/progression, or last follow-up, or death from ovarian cancer, whichever came first. The data regarding patients with no evidence of recurrence or death from ovarian cancer were censored at the date of last follow-up.</p><p>The comparisons and distributions of characteristics between the two groups and subgroups were conducted with the Chisquare or Student's or Mann-Whitney U tests. Median survival was evaluated using the Kaplan-Meier method, and a log-rank test was used to compare survival between two randomised groups. Treatment effects were estimated by using the Cox regression model when proportional hazards could be assumed. Because there was no prespecified plan to stratify or adjust for multiple comparisons, a multivariable analysis was performed to evaluate efficacy outcomes with the adjustment for the important baseline confounders, such as FIGO stage, neoadjuvant chemotherapy and residual diseases. The previous analysis of 12-month nonprogression rate has been conducted (two-sided α = 0.05). <ref type="bibr" target="#b4">5</ref> Here, prespecified PFS and OS analyses were performed after sufficient follow-up for the observation of 160 (80%) events of disease progression, or death from ovarian cancer, using a two-sided α of 0.05.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p>Censored on September 10, 2018 (3 years after the last patient enrolled), the median follow-up time was 69.1 months (interquartile range, 53.1-83.9). The median time to the first cycle of standard IV chemotherapy since primary surgery were 49 days and 15 days in the DD-EPIC and IV group, respectively (Student's t test, P &lt; 0.001), but the period of front-line chemotherapy was similar between the two groups, with only a 0.2-month increase in the DD-EPIC group.</p><p>Totally, 122 patients (56.3%) died from ovarian cancer: 54 (50.9%) of those in the DD-EPIC group and 68 (62.4%) of those in the IV group, respectively. The median overall survival was 67.5 (95% CI 57.0-78.1) months in the DD-EPIC group and 46.3 (95% CI 35.1-57.5) months in the IV group, a difference of 21.2 months. The probability rate of overall survival at 5 years was 61.0% with DD-EPIC and 38.2% with IV chemotherapy alone (HR for death from ovarian cancer, 0.70; 95% CI, 0.49-1.00; P = 0.047; <ref type="figure" target="#fig_1">Fig. 1a)</ref>. Patients in the DD-EPIC group showed significantly prolonged PFS compared with those in the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR 0.64, 95% CI 0.47-0.86, P = 0.003; <ref type="figure" target="#fig_1">Fig. 1b)</ref>. Similar findings were observed in the time to first and second subsequent anticancer therapies ( <ref type="figure" target="#fig_1">Supplementary Figs. S1,  S2</ref>). The survival benefit of DD-EPIC remained after the adjustment for FIGO stage, neoadjuvant chemotherapy and residual disease ( <ref type="table">Supplementary Table S1</ref>). Subgroup analyses of overall survival <ref type="figure" target="#fig_1">(Fig. 1c)</ref> and progression-free survival ( <ref type="table">Supplementary Table S2</ref>) showed that the benefit of DD-EPIC was consistent across most of the baseline risk factors and post hoc subgroups.</p><p>The maintenance therapy and the second-line therapy are listed in <ref type="table">Supplementary Table S3</ref>. During the extended follow-up of overall survival, we did not observe any chemotherapeutic-related adverse events added.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>Since the negative result of GOG252 with the reduction of the cisplatin dose from 100 mg/m 2 to 75 mg/m 2 , <ref type="bibr" target="#b3">4</ref> IP chemotherapy in ovarian cancer has remained controversial, particularly in the improvement of study design. Recently, there were several novel study designs of IP chemotherapy, such as hyperthermic intraperitoneal chemotherapy (HIPEC), <ref type="bibr" target="#b5">6</ref> pressurised intraperitoneal aerosol chemotherapy (PIPAC), <ref type="bibr" target="#b6">7</ref> early postoperative Intraperitoneal chemotherapy (EPIC), amongst others. HIPEC demonstrated a survival benefit in patients who underwent neoadjuvant chemotherapy followed by interval cytoreduction. <ref type="bibr" target="#b5">6</ref> However, the effect of HIPEC is unclear in patients who underwent primary debulking surgery. PIPAC trial was a phase I study with intraperitoneal cisplatin and doxorubicin applied. <ref type="bibr" target="#b6">7</ref> Here, we present the final OS result of DD-EPIC in advanced ovarian cancer patients. With the median follow-up of 69.1 months, a remarkable overall survival benefit was recorded in favour of DD-EPIC with a 21.2-month improvement.</p><p>EPIC, as an approach of perioperative IP chemotherapy, has been used as an adjunct to oncologic surgery for peritoneal carcinomatosis, colorectal and gastric cancer, and other solid tumours. <ref type="bibr" target="#b7">8</ref> Goodman et al. indicated that EPIC could minimise non-uniform drug distribution, and eliminate residual cancer cell entrapment in post-operative fibrin deposits compared with the post-operative IP combined with IV therapy; and it is administered from postoperative day 1 with continued daily therapy for 5-7 days. <ref type="bibr" target="#b7">8</ref> Klaver et al. compared the two IP chemotherapy designs (HIPEC and EPIC) in colorectal peritoneal carcinomatosis. They found that both EPIC and HIPEC were effective in prolonging survival, but the beneficial effect of EPIC on survival seemed to be more pronounced than that of HIPEC. <ref type="bibr" target="#b8">9</ref> In the current trial, DD-EPIC was generally performed 4-7 days after surgery with continued weekly therapy for four doses. The addition of DD-EPIC, with only a median 0.2-month increase of the front-line therapy, did not obviously delay the start of standard IV chemotherapy. In total, there were 21.9% and 30.6% of patients identified to be platinum resistant with progression-free interval &lt; 6 months in the DD-EPIC and IV group, respectively. It is reasonable to address that DD-EPIC might decrease platinum resistance and prolong non-progression interval.</p><p>Etoposide has previously been considered as a primary therapy for ovarian cancer. <ref type="bibr" target="#b9">10</ref> In a pharmacokinetic study of IP cisplatin and etoposide, the free (non-protein-bound) etoposide peritoneal exposure was 65-fold greater than that in plasma. <ref type="bibr" target="#b10">11</ref> Consistent with our previous study, <ref type="bibr" target="#b9">10</ref> IP chemotherapy of cisplatin and etoposide have also been reported to be effective in the primary treatment of ovarian cancer. <ref type="bibr" target="#b11">12</ref> There were no data about the usage of etoposide during the first-line therapy, however, we found some evidences from the second-line therapy, which indicated that etoposide might eliminate chemoresistant cancer cells. For example, recently, a combination therapy of apatinib and etoposide showed an impressive median objective response rate (ORR) of 54% (95% CI 36.6-71.2%) in patients with chemoresistant or chemorefractory recurrent ovarian cancer. <ref type="bibr" target="#b12">13</ref> In comparison, a previous report of apatinib alone in chemoresistant gastric cancer indicated that the ORR of apatinib alone was 6.4% and 13.0% for 850 mg once a day and for 425 mg twice a day, respectively, <ref type="bibr" target="#b13">14</ref> which is far less than the combined effect with etoposide in ovarian cancer. Therefore, it could be reasonable to address that ovarian cancer patients with chemoresistance may benefit more from etoposide rather than apatinib. This may partly explain why the platinum-resistant rate in the DD-EPIC group was much lower than that in the IV group (21.9% vs. 30.6%) in the current AICE trial. Following the overall survival data,   the pattern of DD-EPIC combining cisplatin and etoposide may be more useful to decrease 12-month progression, thus improving PFS and OS. Key points of the AICE study:</p><p>• Validation of more than 30 years' experience with IP of cisplatin and etoposide in China.</p><p>• A high dose of cisplatin with total 200 mg/m 2 , obviously benefits those patients with age &lt; 56 years old.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 1</head><label>1</label><figDesc>Treatment effect on survival. a Overall survival in all patients. b Progression-free survival in all patients. c Treatment effect on overall survival in major subgroups</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Survival benefits of dose-dense early postoperative intraperitoneal. . . T Shi et al.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1234567890">();,:</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p>The study was initiated by Shanghai Gynecologic Oncology Group. We wish to thank Dr. Jonathan Berek at Stanford University, Dr. Michael A. Bookman at Kaiser Permanente San Francisco and Dr. Robert L. Coleman at MD Anderson Cancer Center for their valuable comments on the manuscript. We thank Kay Chong at University of Oxford for the language editing. We would like to thank the trial participants and the trial site personnel who assisted with the trial, as well as the members of the Data Safety Monitoring Committee.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>The study was designed by R.Z. and S.C. Dr. Michael A. Bookman, who is not the author, gave the comments to the study design. The data were gathered by Y.L., analysed and explained by H.J., R.J. and T.S. The paper was written by T.S. (including first draft) and edited and approved by all contributing authors. The authors vouch for the data, its analysis and adherence to the study protocol and statistical analysis plan. The decision to publish the paper was made by all contributing authors.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ADDITIONAL INFORMATION</head><p>Supplementary information is available for this paper at https://doi.org/10.1038/ s41416-019-0543-1.</p><p>Competing interests: The authors declare no competing interests.</p><p>Ethics approval and consent to participate: The trial protocol was compliant with good clinical practice guidelines and the Declaration of Helsinki, and was approved by the ethics committee of Fudan University Cancer Hospital in 18 April 2009 (IRB number: 090371-2). This trial was registered with ClinicalTrials.gov's number NCT01669226. All patients provided written informed consent before participation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding:</head><p>The study was supported by funds from the Chinese Anti-Cancer Association (Grant no. HYXH1002), the Zhongshan Development Program (Grant no. 016) and the Shanghai Municipal Health Project (Grant no. 2013ZYJB0201), but the funders had no role in the design, conduct, analysis and interpretation of the data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent to publish:</head><p>All patients who participated in this trial gave their consents for publication.</p><p>Data availability: Each original data and Case Report Form for each patient used in the article can be accessed from the ethics committee of each participant hospital.</p><p>Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).</p><p>Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">V</forename><surname>Hannigan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>O'toole</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">D</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Young</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="page" from="1950" to="1955" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Intraperitoneal cisplatin and paclitaxel in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Baergen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="34" to="43" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">N</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Clark-Pearson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">F</forename><surname>Carson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1001" to="1007" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Disilvestro</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.18.01568</idno>
		<ptr target="https://doi.org/10.1200/JCO.18.01568" />
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol. JCO1801568</title>
		<imprint>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Dai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="12" to="18" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hyperthermic intraperitoneal chemotherapy in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Driel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Koole</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Sikorska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Schagen Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">W R</forename><surname>Schreuder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H M</forename><surname>Hermans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="230" to="240" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Tempfer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Giger-Pabst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Seebacher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Dogan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">A</forename><surname>Rezniczek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="23" to="30" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mcpartland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Detelich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">W</forename><surname>Saif</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Gastrol. Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="45" to="57" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">L</forename><surname>Klaver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hendriks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Lomme</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Rutten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">P</forename><surname>Bleichrodt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">H</forename><surname>De Hingh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg. Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="475" to="482" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Impacts of chemotherapy on long-term survival of patients with advanced epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Zang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhonghua fu chan ke za zhi</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="738" to="741" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Zimm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Cleary</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">E</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Andrews</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1712" to="1716" />
			<date type="published" when="1987" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">B</forename><surname>Howell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kirmani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">E</forename><surname>Fau -Lucas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lucas We Fau -Zimm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Zimm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Goel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="137" to="145" />
			<date type="published" when="1990" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">X</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">F</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1239" to="1246" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Bai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3219" to="3225" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
